Omeros has been granted a patent for compounds that inhibit MASP-2 activity. The patent includes compositions of these compounds and outlines methods for their production and use, with a specific structural claim for one of the compounds. GlobalData’s report on Omeros gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Omeros, Peptide pharmacophores was a key innovation area identified from patents. Omeros's grant share as of June 2024 was 45%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent US12030853B2 outlines a novel compound characterized by a specific structural formula, referred to as Structure (I). The claims detail various configurations of this compound, including the substitution of specific groups denoted as R1, R2a, R2b, R2c, R2d, R3, and R4. Notably, R1 can be selected from pyridinyl, pyrrolopyridinyl, or benzoimidazolyl groups. The claims further specify that at least one of the substituents R2a, R2b, R2c, and R2d may include a range of functional groups such as alkoxy, cyano, halo, and various carbonyl derivatives, with R5 and R6 being independently defined as hydrogen or C1-C6 alkyl. The patent also allows for variations in the value of n, which can be 0, 1, or 2, and provides specific structures for R4 when n is set to 2.
In addition to the compound itself, the patent claims the inclusion of a pharmaceutical composition that comprises the compound or its stereoisomers, tautomers, or pharmaceutically acceptable salts, combined with a suitable carrier or excipient. This suggests potential applications in therapeutic contexts, although the specific uses or benefits of the compound are not detailed in the claims. The comprehensive nature of the claims indicates a focus on the structural diversity and potential functionalization of the compound, which may be relevant for further research and development in pharmaceutical applications.
To know more about GlobalData’s detailed insights on Omeros, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
